A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients With Locally Advanced or Metastatic Epithelial Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Duligotuzumab (Primary)
- Indications Carcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Genentech
- 02 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
- 08 Sep 2017 Planned End Date changed from 31 Aug 2017 to 1 Mar 2018.
- 04 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Aug 2017.